We are committed to participating in as many existing IBD trials as possible to provide the best treatment opportunities for our patients.

Our goal is to contribute to the research that will one day find a cure for IBD, and in the meantime, to help our patients live more fulfilling, symptom-free lives.

Active Crohn's clinical trials

Active Crohn's clinical trials

New medical therapies in the IBD pipeline (for patients who have failed steriods, immunomodulators and/or biologic therapy)

ADVANCE

Rizankizumab (anti-IL 23) 

An open label extension study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy 

MOTIVATE

Rizankizumab (anti-IL 23)  

A study enrolling moderate to severe Crohn’s disease patients that have failed one or more biologic therapy

U-Exceed

Upadactinib (anti-Jak 1)

A study enrolling moderate to severe active Crohn's disease patients who have inadequately responded or are intolerant of prior biologic treatment

U-Exceed

Upadactinib (anti-Jak 1)

A study enrolling moderate to severe active Crohn's disease patients who have inadequately responded or are intolerant of prior biologic treatment

Yellowstone

Oral Ozanimod (S1P1 and S1P5 agonist)

Phase 3 study of oral small molecule for moderate to severe active Crohn's disease

Early diagnosis/treatment of Crohn's

Explorer

 Vedolizumab IV, Adalimumab SC, and oral Methotrexate  

An open label, triple therapy, phase 4 study for early treatment of Crohn’s disease

For patients with moderate to severe Crohn's or fistulizing Crohn's patients

GALAXI

Guselkumab (anti-IL 23) 

A phase 2/3 study enrolling moderate to severe Crohn’s disease patients or fistulizing Crohn’s disease patients, with past colitis, ileitis, or ileocolitis

SEAVUE

This phase 3B trial is a first-of-its-kind, head-to-head study of the effectiveness of Ustekinumab (Stelara) versus Adalimumab (Humria) in the treatment of severe Crohn’s disease that has not been previously treated with a biologic therapy. There is no placebo in this trial—all patients will receive an active medication.
 
Active Ulcerative Colitis clinical trials

Active Ulcerative Colitis clinical trials

INCYTE

Itacitinib (anti-Jak 1)

A phase 2 study for moderate to severe ulcerative colitis

INSPIRE

Risankizumab (anti-IL 23) 

A study enrolling moderate to severe active ulcerative colitis patients who have failed a prior biologic treatment

U-Achieve

Upadacitinib (anti-Jak 1) 

A study enrolling moderate to severe ulcerative colitis patients that failed one or more biologic therapy

Registry Trials

Registry Trials

TARGET

This is a 5-year longitudinal observational study of patients undergoing therapy for inflammatory bowel disease. The study is open to all IBD patients (Crohn’s, UC and Indeterminate IBD).

SBS Registry

A registry collecting data on patients with short bowel syndrome
Other/miscellaneous trials

Other/miscellaneous trials

DINE - Nutrition study

Trial of the effectiveness of a Mediterranean diet versus a specific carbohydrate diet to induce remission of Crohn's disease